Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Exercise hormone irisin mitigates endothelial barrier dysfunction and microvascular leakage–related diseases
Jianbin Bi, Jia Zhang, Yifan Ren, Zhaoqing Du, Yuanyuan Zhang, Chang Liu, Yawen Wang, Lin Zhang, Zhihong Shi, Zheng Wu, Yi Lv, Rongqian Wu
Jianbin Bi, Jia Zhang, Yifan Ren, Zhaoqing Du, Yuanyuan Zhang, Chang Liu, Yawen Wang, Lin Zhang, Zhihong Shi, Zheng Wu, Yi Lv, Rongqian Wu
View: Text | PDF
Research Article Cell biology Vascular biology

Exercise hormone irisin mitigates endothelial barrier dysfunction and microvascular leakage–related diseases

  • Text
  • PDF
Abstract

Increased microvascular leakage is a cardinal feature of many critical diseases. Regular exercise is associated with improved endothelial function and reduced risk of cardiovascular disease. Irisin, secreted during exercise, contributes to many health benefits of exercise. However, the effects of irisin on endothelial function and microvascular leakage remain unknown. In this study, we found that irisin remarkably strengthened endothelial junctions and barrier function via binding to integrin αVβ5 receptor in LPS-treated endothelial cells. The beneficial effect of irisin was associated with suppression of the Src–MLCK–β-catenin pathway, activation of the AMPK-Cdc42/Rac1 pathway, and improvement of mitochondrial function. In preclinical models of microvascular leakage, exogenous irisin improved pulmonary function, decreased lung edema and injury, suppressed inflammation, and increased survival. In ARDS patients, serum irisin levels were decreased and inversely correlated with disease severity and mortality. In conclusion, irisin enhances endothelial barrier function and mitigates microvascular leakage–related diseases.

Authors

Jianbin Bi, Jia Zhang, Yifan Ren, Zhaoqing Du, Yuanyuan Zhang, Chang Liu, Yawen Wang, Lin Zhang, Zhihong Shi, Zheng Wu, Yi Lv, Rongqian Wu

×

Figure 1

Irisin strengthened endothelial barrier function and reduced LPS-induced endothelial cell hyperpermeability.

Options: View larger image (or click on image) Download as PowerPoint
Irisin strengthened endothelial barrier function and reduced LPS-induced...
HMVECs and HUVECs were treated with 10 nM irisin immediately after 500 ng/mL LPS administration. (A) Phalloidin and VE-cadherin staining for assessing cytoskeletal remodeling and adherens junction integrity in HMVECs 2 hours after LPS and irisin treatment. Scale bar: 20 μm. Asterisks in the Phalloidin and VE-cadherin staining represent gaps between the cells. (B) Gap areas in the total areas. (C) Relative permeability of FITC-labeled albumin 2 hours after LPS and irisin treatment in HMVECs. (D) Transendothelial electrical resistance (TER) in irisin- and control-treated human microvascular endothelial cells (HMVECs). (E) TER in irisin- and control-treated HMVECs after 500 ng/mL LPS administration. (F) Phalloidin (scale bar: 10 μm), VE-cadherin (scale bar: 5 μm), and β-catenin (scale bar: 5 μm) staining for assessment of cytoskeletal remodeling and adherens junction integrity in HUVECs 2 hours after LPS and irisin treatment. Arrows in the VE-cadherin/β-catenin staining represent gaps between the cells. (G) TER in irisin- and control-treated HUVECs. (H) Maximum TER relative to baseline. (I) TER in irisin- and control-treated HUVECs after 500 ng/mL LPS administration. (J) Relative permeability of FITC-labeled albumin 2 hours after LPS and irisin treatment in HUVECs. n = 6 per group, mean ± SEM, *P < 0.05 versus the sham group, #P < 0.05 versus the LPS group. The t test was used to analyze the differences between 2 groups (H), and 1-way ANOVA was used to analyze the differences among 3 or more groups (B, C, and J).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts